Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy, Safety and Tolerability of Modified-Release Methylphenidate (MPH-MR) in Chinese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)
Modified-release methylphenidate was superior to placebo in improving ADHD symptoms and functioning in Chinese pediatric patients with ADHD. Modified-release methylphenidate had a good safety and tolerability profile. Trial Registration http://www.chinadrugtrials.org.cn/ Identifier: CTR20180056 (registered on 21 May 2018).
Authors
- Michaela Ruhmann
- Anke Mayer
- Oliver Dangel
- Richard Ammer (ORCID: https://orcid.org/0000-0003-0167-4894)
- Haibo Li (ORCID: https://orcid.org/0000-0002-6512-3912)
- Yi Zheng (ORCID: https://orcid.org/0000-0001-8034-1195)
- Huaqing Liu (ORCID: https://orcid.org/0000-0001-7723-9309)
- Xiuxia Wang
Institutions
- Hebei Medical University (CN)
- Capital Medical University (CN)
- Jilin University (CN)
- Second Hospital of Hebei Medical University (CN)
- University Hospital Münster (DE)
- Beijing Anding Hospital (CN)
- Medice (Germany) (DE)
- First Hospital of Jilin University (CN)
- Beijing HuiLongGuan Hospital (CN)
Publication Details
- Journal
- CNS Drugs
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1007/s40263-024-01136-6
- Citations
- 3
- Primary Topic
- Attention Deficit Hyperactivity Disorder
- Type
- article
- Field-Weighted Citation Impact
- 1.16